Level B· Emerging clinical evidence with positive signalsClinical TrialPubMed

Stromal vascular fraction-enriched platelet-rich plasma therapy reverses the effects of androgenetic alopecia.

Butt G., Hussain I., Ahmad FJ., Choudhery MS.

Clinical Trial on Hair Loss, Hair Regeneration, published in J Cosmet Dermatol (2019) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
J Cosmet Dermatol (2019)
Country
England
Reported sample size
—
Source database
PubMed
PMID
31541565
DOI
10.1111/jocd.13149
Citations
34

Abstract (original English)

Background Since antiquity, humans have been trying to devise remedies to cure androgenetic alopecia (AGA). These efforts include use of oral and topical concoctions and hair transplant strategies. As AGA affects people of all colors and creed, there has been a continuous effort to find a magic bullet against AGA. Unfortunately, to date, all the strategies to negate AGA effects have limitations and thus require new treatment options. Aim To evaluate the efficacy of use of stromal vascular fraction (SVF) in androgenetic alopecia patients. Methods Stromal vascular fraction was obtained by enzymatic digestion of autologous adipose tissue. The patients were divided into two groups, that is, platelet-rich plasma (PRP) group and SVF-PRP group. In PRP group, only PRP was injected, while in SVF-PRP group a mixture of PRP and SVF was injected in affected scalp areas. After two sessions (4 weeks apart), the patients in both groups were assessed and analyzed using various parameters. Results Mean hair density in PRP group was increased from 52.44 hair/cm 2 to 63.72 hair/cm 2 (21.51% increase); while in SVF-PRP group, it was 37.66 hair/cm 2 before treatment and 57.11 hair/cm 2 after SVF-PRP therapy (51.64% increase). Percentage reduction in pull test was more significant in SVF-PRP group (80.78 ± 5.84) as compared to PRP group (34.01 ± 22.44). The physician and patient assessment scores al

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
Adipose TissueAdultAlopeciaBlood Transfusion, AutologousCombined Modality TherapyFemaleHairHumansMalePhotography

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research